RecruitingNCT05786066
About this title
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Read the official source — NCT05786066Official study titleThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
In West HavenDepression, Suicidality, ...Medication studyAges 21–65
- Countries
- United States
- Sponsor
- Yale University
RecruitingACTRN12622000851763
Official study titleA phase 1,First-in-Human, open-label, Safety, Tolerability and Pharmacokinetic Study of Single-Ascending Doses of VLS-01 in Healthy Adult Volunteers
In New ZealandDepressionInterventional studyAges 21–45
- Countries
- New Zealand
- Sponsor
- Viridia Life Sciences Australia Pty Ltd
Not Yet RecruitingACTRN12626001250325
Official study titleA Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Food on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PNV-8297 in Healthy Volunteers
This study isn't recruiting yet.
In AustraliaDepressionInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- ProNovo Therapeutics Australia Pty Ltd
Not Yet RecruitingACTRN12626001249347
Official study titleA Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PNV-8297 in Healthy Volunteers
This study isn't recruiting yet.
In AustraliaDepressionInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- ProNovo Therapeutics Australia Pty Ltd
Not Yet RecruitingACTRN12622001238763
Official study titleTowards a better understanding of frailty in people with severe mental illness: a longitudinal analysis of the UK Biobank
This study isn't recruiting yet.
In United KingdomDepression, Schizophrenia, ...Observational studyAges 37–73
- Countries
- United Kingdom
- Sponsor
- The University of Queensland
Not Yet RecruitingNCT06489990
This study isn't recruiting yet.
In BeijingDepressionPlacebo comparison
- Countries
- China
- Sponsor
- Capital Medical University
Not Yet RecruitingACTRN12625001326482
Official study titleA Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GM-28K in Healthy Adult Participants
This study isn't recruiting yet.
In AustraliaDepressionInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- Grey Matter Pharma Pty Ltd
CompletedACTRN12610000998044
Official study titleA comparative trial of sequential bilateral and unilateral right sided priming repetitive transcranial magnetic stimulation on the severity of depressive symptoms in major depressive disorder.
This study has finished and is no longer accepting participants.
Location not clearly listedDepressionInterventional studyAges 18–70
- Countries
- Sponsor
- Healthscope
Enrolling By InvitationNCT01809080
Official study titleInvestigation Into the Interaction Between Genes and Stress in the Etiology of Depression in Interns
This study is by invitation only.
In Ann ArborDepressionObservational study
- Countries
- United States
- Sponsor
- University of Michigan
Enrolling By InvitationNCT06758518
Official study titleAre Anxiety and Depressive Disorders Related to Carpal Tunnel Syndrome in Medical Students?
This study is by invitation only.
In IoanninaDepressionObservational study
- Countries
- Greece
- Sponsor
- University of Ioannina
Not recruitingEUCTR 2016-001637-27
This study isn't currently recruiting.
Recruitment status comes from the linked ISRCTN record. Both registries list the identifiers for the same study.
In United KingdomDepressionHistorical research record
- Countries
- United Kingdom
- Sponsor
- South London and Maudsley NHS Foundation Trust [...] 1. South London and Maudsley NHS Foundation Trust 2. King's College London
TerminatedNCT04821271
Official study titleAn Investigation of the Antidepressant Effects of the mGlu2/3 Receptor Antagonist TS-161 in Treatment-Resistant Depression
This study ended early.
In BethesdaDepressionMedication studyAges 18–65
- Countries
- United States
- Sponsor
- National Institute of Mental Health (NIMH) (Government agency)